Eli Lilly And Company ((LLY)), AKOUOS INC ((AKUS)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The recent clinical study titled ‘A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma’ aims to assess the safety and tolerability of a novel gene therapy. Sponsored by Akouos, Inc., in collaboration with Eli Lilly and Company, this study focuses on a single unilateral administration of AAVAnc80-antiVEGF to treat vestibular schwannoma, a condition affecting the balance and hearing nerves.
The intervention being tested is a combination product: AAVAnc80-antiVEGF, delivered via the Akouos Delivery Device. This therapy involves intracochlear administration intended to improve product performance and patient outcomes.
This interventional study employs a non-randomized, sequential intervention model without masking, primarily aimed at treatment. It involves three experimental cohorts receiving varying dose levels of the gene therapy.
The study officially started on January 17, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on August 4, 2025, indicating ongoing recruitment and progress.
For investors, this study could signal significant advancements in gene therapy, potentially impacting the stock performance of both Akouos and Eli Lilly. As the trial progresses, positive outcomes may boost investor confidence and position these companies favorably within the competitive biotech industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.